Such is the case with Poli ADP-ribose polymerase (PARP) inhibitors in BRCA-mutated breast cancer [12,13], serine/threonine protein kinase (AKT) inhibitors in phosphatidylinositol-3-OH kinase (PI3K)/AKT/Phosphatase and tensin homologue (PTEN)-altered TNBC [14,15], and trophoblast cell surface antigen-2 (Trop-2) directed antibody-drug conjugate (ADC) sacituzumab govitecan in heavily pre-treated TNBC [16]. The gene discussed is AKT1; the disease is breast carcinoma.